Short answer
CASTLE BIOSCIENCES INC (CSTL) filed its Q1 2026 10-Q quarterly report on May 6, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $84M (down 4.9% year over year) with net income of −$15M.
Q1 2026 key financials · XBRL
- Revenue
- $84M
- −4.9% YoY
- Net income
- −$15M
- +43.8% YoY
- Operating margin
- -22.0%
- EPS (diluted)
- −$0.49
- +45.6% YoY
Source: XBRL data from the CASTLE BIOSCIENCES INC (CSTL) Q1 2026 10-Q on SEC EDGAR. USD.
CASTLE BIOSCIENCES INC Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Test reports 26,933, up 10% YoY; dermatology 14,696, up 6%, while TissueCypher 11,745, up 58%
- AdvanceAD-Tx received approximately 650 orders during Q1 limited-access launch
- DecisionDx-SCC worst-performing line, 3,702 reports vs 4,375 YoY
- Management plans phased AdvanceAD-Tx availability throughout remainder of 2026
- Headwinds include reimbursement uncertainty, macroeconomic disruptions, tariffs, higher interest rates, and Medicare noncoverage of DecisionDx-SCC
Risk Factors
- New geopolitical risk: U.S.-Iran conflict since February 2026, with sanctions, export controls, and Strait of Hormuz closure risk
- Most material update: DecisionDx-SCC noncovered under Novitas LCD effective April 24, 2025, reducing expected 2026 revenue contribution
- Regulatory reimbursement risk: MolDX placed DecisionDx-SCC reconsideration on waiting list without scheduled Open Meeting date
- Operational market risk: Revenue primarily dependent on DecisionDx-Melanoma and TissueCypher sales for the next several years
- Financial risk: March 31, 2026 net loss $14.5 million and accumulated deficit $238.8 million
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other CASTLE BIOSCIENCES INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.